SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, today announced that it has signed a Cooperative Research and Development Agreement with the National Cancer Institute , part of the National Institutes of Health, to create reference materials and positive controls for cancer assays. The CRADA will investigate the development of methods to mix and accurately quantitate control DNA biosynthetics spiked into a genomic DNA background and cell-free circulating tumor DNA for next-generation DNA sequencing applications.